Conformal Medical focuses on innovative solutions for patients with atrial fibrillation (Afib), particularly addressing the associated risk of stroke. The company has developed the CLAAS® System, a foam device specifically designed to occlude the left atrial appendage (LAA), which is a common site for blood clot formation in Afib patients. This one-time procedure aims to significantly reduce the risk of stroke without the need for long-term oral anticoagulant therapy, which can pose challenges due to the risk of bleeding and the necessity for ongoing monitoring. The CLAAS device is tailored to fit each patient's unique anatomy and is intended to be permanently placed in the heart during a single procedure.

The CLAAS System is currently under investigation in several clinical trials, including the Conformal Early Feasibility Study and the CONFORM Pivotal Trial, among others. These studies aim to gather data on the device's safety and efficacy, with findings being published in peer-reviewed journals. It is important to note that the CLAAS device is still in the investigational stage and is not yet approved for clinical use in any region. Conformal Medical is committed to advancing stroke prevention strategies for Afib patients through rigorous clinical research and innovative device development.

United States

Conformal Medical develops medical devices to prevent stroke in patients with non-valvular atrial fibrillation. 

The company's proprietary technology will help left atrial appendage closure meet its true potential.

Conformal Medical

Company Details